Publicaciones en colaboración con investigadores/as de University of Eastern Finland (31)

2024

  1. A genome-wide association meta-analysis of all-cause and vascular dementia

    Alzheimer's and Dementia, Vol. 20, Núm. 9, pp. 5973-5995

  2. Discovery and in vitro Evaluation of Novel Serotonin 5-HT2A Receptor Ligands Identified Through Virtual Screening

    ChemMedChem, Vol. 19, Núm. 14

2023

  1. Development and Characterization of Novel Selective, Non-Basic Dopamine D2 Receptor Antagonists for the Treatment of Schizophrenia

    Molecules, Vol. 28, Núm. 10

  2. Discovery of novel arylpiperazine-based DA/5-HT modulators as potential antipsychotic agents – Design, synthesis, structural studies and pharmacological profiling

    European Journal of Medicinal Chemistry, Vol. 252

  3. Erratum: Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores (Nature communications (2021) 12 1 (3417))

    Nature communications

  4. Novel multi-target ligands of dopamine and serotonin receptors for the treatment of schizophrenia based on indazole and piperazine scaffolds-synthesis, biological activity, and structural evaluation

    Journal of enzyme inhibition and medicinal chemistry, Vol. 38, Núm. 1, pp. 2209828

2022

  1. Activity and Expression of Carboxylesterases and Arylacetamide Deacetylase in Human Ocular Tissues

    Drug metabolism and disposition: the biological fate of chemicals, Vol. 50, Núm. 12, pp. 1483-1492

  2. Allosteric modulation of dopamine D2L receptor in complex with Gi1 and Gi2 proteins: the effect of subtle structural and stereochemical ligand modifications

    Pharmacological Reports, Vol. 74, Núm. 2, pp. 406-424

  3. Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

    Acta Neuropathologica, Vol. 144, Núm. 5, pp. 821-842

  4. In vitro and in vivo evaluation of antioxidant and neuroprotective properties of antipsychotic D2AAK1

    Neurochemical Research, Vol. 47, Núm. 6, pp. 1778-1789

  5. Multitarget Derivatives of D2AAK1 as Potential Antipsychotics: The Effect of Substitution in the Indole Moiety

    ChemMedChem, Vol. 17, Núm. 15

  6. New insights into the genetic etiology of Alzheimer's disease and related dementias

    Nature genetics, Vol. 54, Núm. 4, pp. 412-436

2021

  1. Breast cancer risk genes - Association analysis in more than 113,000 women

    New England Journal of Medicine, Vol. 384, Núm. 5, pp. 428-439

  2. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

    Nature communications, Vol. 12, Núm. 1, pp. 3417

  3. N-(3-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}propyl)-1H-indazole-3-carboxamide (D2AAK3) as a potential antipsychotic: In vitro, in silico and in vivo evaluation of a multi-target ligand

    Neurochemistry International, Vol. 146

  4. Subclone eradication analysis identifies targets for enhanced cancer therapy and reveals L1 retrotransposition as a dynamic source of cancer heterogeneity

    Cancer Research, Vol. 81, Núm. 19, pp. 4901-4909

2020

  1. N-(2-hydroxyphenyl)-1-[3-(2-oxo-2,3-dihydro-1h-benzimidazol-1-yl)propyl]piperidine-4-carboxamide (d2aak4), a multi-target ligand of aminergic gpcrs, as a potential antipsychotic

    Biomolecules, Vol. 10, Núm. 2

  2. PET study of ocular and blood pharmacokinetics of intravitreal bevacizumab and aflibercept in rats

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 154, pp. 330-337

2019

  1. Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (Nature Genetics, (2019), 51, 3, (414-430), 10.1038/s41588-019-0358-2)

    Nature Genetics

  2. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing

    Nature Genetics, Vol. 51, Núm. 3, pp. 414-430